Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06895070 · ClinicalTrials.gov registry record · NA
XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)
A NA study of Heart Failure and Heart Transplant, sponsored by XVIVO Perfusion.
- Recruiting
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 14
- Study locations
NCT06895070: Recruiting NA study of Heart Failure and Heart Transplant, sponsored by XVIVO Perfusion.
NCT06895070 is a NA study of Heart Failure and Heart Transplant that is actively recruiting participants, run by XVIVO Perfusion. The registered enrollment target is 60 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower). The trial reports 14 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06895070, a NA study of Heart Failure and Heart Transplant, is actively recruiting participants, sponsored by XVIVO Perfusion.
- RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to evaluate if Non-Ischemic Heart Preservation (NIHP) of extended criteria donor hearts using the XVIVO Heart Preservation System (XHPS) is a safe and effective way to preserve and transport hearts for transplantation.
Primary Outcome
The percentage of patient treatment success rate at 30-days post transplantation. The treatment success is defined as freedom from treatment failure.
Conditions Studied
Interventions
- DEVICE Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Assist Transport (XHAT)
Study Locations (14)
California
- UC San Diego Health - La Jolla
- Cedars Sinai Medical Center - Los Angeles
- University of California Los Angeles - Los Angeles
- Stanford University - Stanford
New York
- NYU Langone - New York
- Columbia University Medical Center/New York Presbyterian Hospital - New York
Georgia
- Emory University Hospital - Atlanta
Illinois
- Northwestern Memorial Hospital - Chicago
Missouri
- Washington University - Barnes Jewish Health Hospital - St Louis
Nebraska
- University of Nebraska Medical Center - Omaha
North Carolina
- Duke University Medical Center - Durham
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-07-10 |
| Est. Completion | 2031-05 |
| Phase | NA |
What NCT06895070 shows while recruiting
NCT06895070 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower).
The record links to 3 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Assist Transport (XHAT) is the first listed.
NCT06895070 lists 14 locations in 10 states (California, New York, Georgia).
Frequently Asked Questions
What is clinical trial NCT06895070 about?
NCT06895070 is a clinical study titled "XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)". The purpose of this study is to evaluate if Non-Ischemic Heart Preservation (NIHP) of extended criteria donor hearts using the XVIVO Heart Preservation System (XHPS) is a safe and effective way to preserve and transport hearts for transplantation.
What is the current status of trial NCT06895070?
This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2025-07-10. Estimated completion is 2031-05.
What conditions does trial NCT06895070 study?
This clinical trial studies the following conditions: Heart Failure, Heart Transplant, Transplant; Failure, Heart.
What interventions are being tested in trial NCT06895070?
The interventions under investigation include: Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Assist Transport (XHAT) (DEVICE).
Who is sponsoring clinical trial NCT06895070?
This trial is sponsored by XVIVO Perfusion, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06895070 being conducted?
This trial has 14 study locations across California, Georgia, Illinois, Missouri, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06895070's enrollment target sits among peer trials
60 254th of 397 higher than 131 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver
RECRUITING · NA
-
Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial
RECRUITING · NA
-
Effect of a Quality Improvement Initiative to Address Social Determinants of Health on Rehospitalization Rates in Patients With Heart Failure
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI